EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting

Siyu Chen iD, Zhiquan Liu iD, Chien-Hui Lo, Qing Wang iD, Ke Ning iD, Qi Zhang iD, Jingyu Zhao iD, Yingchun Shen, Yang Sun iD

PNAS Nexus · 02.06.2025 · 4 (6)

DOI: 10.1093/pnasnexus/pgaf168 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PNAS Nexus, online erschienen am 17.06.2025. Verfasst von Siyu Chen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Stanford University School of Medicine, 1651 Page Mill Road, Rm 2220, Palo Alto, CA 94304, USA. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Children's Health Research Institute, International Retinal Research Foundation, NIH.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Glaucoma is a major global cause of irreversible vision loss. It is marked by elevated intraocular pressure (IOP) and the loss of retinal ganglion cells (RGC). While there are medical and surgical therapies for glaucoma aiming to reduce aqueous humor production or enhance its drainage, these treatments are often inadequate for effectively managing the disease. In this study, we developed a targeted therapy for glaucoma by knocking down two genes associated with aqueous humor production (aquaporin 1 [AQP1] and carbonic anhydrase type 2 [CA2]) using Cas13 RNA editing systems. We demonstrate that hfCas13d-mediated knockdown of AQP1 and CA2 significantly lowers IOP in wild-type mice and in a corticosteroid-induced glaucoma mouse model. We show that the lowered IOP results from decreasing aqueous production without affecting the outflow facility; this treatment also significantly promotes RGC survival as compared with untreated control groups. Therefore, CRISPR–Cas-based gene editing may be an effective treatment to lower IOP for glaucomatous optic neuropathy.

Autor:innen und Institutionen

  • Department of Ophthalmology, Stanford University School of Medicine, 1651 Page Mill Road, Rm 2220, Palo Alto, CA 94304, USA.
  • Department of Medicine, John A. Burns School of Medicine, 651 Ilalo St, Honolulu, HI 96813, USA.
  • Department of Ophthalmology, Palo Alto Veterans Administration, 3801 Miranda Ave, Palo Alto, CA 94305, USA.

ORCID-Profile: Siyu Chen, Zhiquan Liu, Qing Wang, Ke Ning, Qi Zhang, Jingyu Zhao, Yang Sun

Förderung

  • Children's Health Research Institute
  • International Retinal Research Foundation
  • NIH

Zitieren

APA

Chen, S., Liu, Z., Lo, C. H., Wang, Q., Ning, K., Zhang, Q., Zhao, J., Shen, Y., & Sun, Y. (2025). Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting. PNAS Nexus, 4(6). https://doi.org/10.1093/pnasnexus/pgaf168

Vancouver

Chen S, Liu Z, Lo CH, Wang Q, Ning K, Zhang Q, et al. Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting. PNAS Nexus. 2025;4(6). doi:10.1093/pnasnexus/pgaf168

BibTeX
@article{Chen2025,
  author = {Chen, Siyu and Liu, Zhiquan and Lo, Chien-Hui and Wang, Qing and Ning, Ke and Zhang, Qi and Zhao, Jingyu and Shen, Yingchun and Sun, Yang},
  title = {Gene therapy for ocular hypertension using hfCas13d-mediated mRNA targeting},
  journal = {PNAS Nexus},
  year = {2025},
  volume = {4},
  number = {6},
  doi = {10.1093/pnasnexus/pgaf168}
}
Kostenlos starten →